A β-lactamase-responsive peptide (BLAP) mimicking defensin-6 self-assembles into nanofibrous nets specifically around MRSA when triggered by the bacteria's own β-lactamase enzyme, trapping it and preventing host cell invasion.
β-lactamase becomes the triggerMRSA's own resistance enzyme activates the peptide to form bacteria-trapping nets — turning the bacteria's greatest defense into its weakness
What the researchers found
BLAP responds specifically to MRSA-secreted β-lactamase by assembling in situ into nanofibrous networks that physically trap the bacteria, preventing host cell invasion and significantly reducing infection and abscess formation in mice.
Why it matters
MRSA kills tens of thousands of people annually and is resistant to nearly all β-lactam antibiotics. By using the very enzyme that confers resistance as the trigger for a bacteria-trapping mechanism, this approach turns MRSA's greatest strength into its downfall — a fundamentally new strategy for combating drug-resistant infections.
The numbers in context
BLAP specifically activated by β-lactamase secreted by MRSA, forming nanonets that trapped and killed drug-resistant bacteria.
How the study worked
BLAP was designed with a self-assembling peptide sequence responsive to β-lactamase cleavage, inspired by human defensin-6's nanonet formation. In vitro testing confirmed β-lactamase-triggered assembly, nanonet formation around MRSA, and prevention of host cell invasion. In vivo efficacy was tested by intramuscular BLAP injection in mice with MRSA infection.
Who was studied
MRSA bacterial cultures and infection models
What this study cannot tell us
Early-stage preclinical study — efficacy in humans is unproven. BLAP works by physically trapping bacteria rather than killing them, so it may need to be combined with immune clearance or other antimicrobials. Not all MRSA strains produce the same levels of β-lactamase. Manufacturing and stability of the peptide for clinical use not addressed. Only tested against one bacterial species.
How to read the evidence
Preliminary evidence from in vitro characterization and in vivo mouse infection model. The concept is innovative and well-demonstrated but far from clinical application.
When this study was published
Published in 2024, representing cutting-edge biomimetic approaches to the antimicrobial resistance crisis.
The bigger picture
Antimicrobial resistance is projected to kill 10 million people annually by 2050. This study demonstrates a paradigm shift: instead of trying to kill resistant bacteria with drugs they can destroy, use their resistance mechanism itself as the weapon trigger. The approach could be adapted for other resistance enzymes, potentially creating an entirely new class of 'resistance-responsive' antimicrobials.
Questions still open
- Could BLAP be combined with conventional antibiotics for synergistic effects against MRSA?
- Can the β-lactamase-responsive design be adapted for other resistant bacterial species?
- What happens to trapped bacteria long-term — does the immune system clear them, or do they eventually escape?
Common questions
How does trapping bacteria work without actually killing them?
Could bacteria develop resistance to this approach?
Read the original research
A β-Lactamase Responsive Peptide Inhibits MRSA Infection through Self-Assembled Nanonet.
Advanced healthcare materials, 13(31), e2402453
Citation
Wu, Minghao; Li, Yuting; Shen, Huaxing; Zhang, Yanan; Cong, Wei; Hu, Xiaochun; Shi, Yejiao; Hu, Honggang. (2024). A β-Lactamase Responsive Peptide Inhibits MRSA Infection through Self-Assembled Nanonet.. Advanced healthcare materials, 13(31), e2402453. https://doi.org/10.1002/adhm.202402453